Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 27:2:51.
doi: 10.1186/1758-5996-2-51.

Lipoprotein (a), C-reactive protein and some metabolic cardiovascular risk factors in type 2 DM

Anthonia O Ogbera  1 , Alfred O Azenabor
Affiliations

Lipoprotein (a), C-reactive protein and some metabolic cardiovascular risk factors in type 2 DM

Anthonia O Ogbera et al. Diabetol Metab Syndr. .

Abstract

Background: Lipoprotein (a) (LP (a) is an independent cardiovascular risk factor that is not widely studied in people of sub-Saharan African origin. The aim of this report is to determine the frequency of occurrence of elevated Lp (a) and possible relationship with total cholesterol (TCHOL), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG), C reactive protein (CRP) and serum uric acid (SUA).

Methods: This is a cross sectional study carried out in 200 Nigerian patients with type 2 DM and 100 sex and age matched healthy Controls aged between 32-86 years. We determined the frequency of occurrence of elevated Lp (a) levels in the study subjects and compared clinical and biochemical variables between type 2 diabetic patients and non-diabetic patients. Clinical and biochemical parameters were also compared between subjects with type 2 DM who had elevated LP (a) and normal LP (a) levels. Long term glycaemic control using glycosylated haemoglobin was determined and compared in the study subjects. Test statistics used include chi square, correlation coefficient analysis and Student's t test.

Results: The mean Lp(a) concentration differed significantly between type 2 diabetic patients and the Control subjects (18.7 (5.8) mg/dl vs 23 (6.8) mg/dl, 0.00001). Similarly, the prevalence of high LP (a) levels in type 2 DM patients was significantly higher than that of the Control subjects (12.5% vs 4%, p-0.019). The mean levels of the lipid profile parameters (TCHOL, LDL-C, TG, LDL/HDL) and CRP were significantly higher in DM patients than in the Control subjects. The mean LP (a) levels were comparable in both sexes and in DM subjects with and without hypertension. TG was the only parameter that differed significantly between subjects with elevated Lp (a) levels and those with normal Lp (a) levels. There was a significant positive correlation (r) between Lp(a) levels and TG, LDL-C. TCHOL, LDL/HDL and uric acid. No association was found between Lp(a) and clinical parameters such as age and anthropometric indices.

Conclusion: We have showed that Lp (a), CRP and other CVS risk factors cluster more in patients with DM than non DM patients. Serum Lp (a) levels are not associated with anthropometric and glycaemic indices.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of Lp (a) in the study subjects.
Figure 2
Figure 2
Comparison of Lp (a) levels in type 2 DM subjects and Control subjects.
Figure 3
Figure 3
Prevalence of cardiovascular risk factors in type 2 DM.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ogbera AO. Burden of diabetes mellitus in Nigeria. Trop Doct. 2007;37(3):153–154. doi: 10.1258/004947507781524746. - DOI - PubMed
    1. Alberti KG, Eckel RH, Grundy SM, Zimmet, Paul Z, Cleeman, James I. Donato Karen Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645. doi: 10.1161/CIRCULATIONAHA.109.192644. - DOI - PubMed
    1. Romics L, Karadi I, Csaszar A, Kostner G. Physiological and Clinical Importance of Lipoprotein(a) J Exp Clin Med. 1990;15:149–1541. - PubMed
    1. Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ, Simari RD. "Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis". Blood. 2001;98(10):2980–7. doi: 10.1182/blood.V98.10.2980. - DOI - PubMed
    1. Heller FR, Jamart J Honore P, Derue G, Novik V, Galanti L. Serum lipoprotein (a) in patients with diabetes mellitus. Diabetes Care. 1993;16(3):819–823. doi: 10.2337/diacare.16.5.819. - DOI - PubMed